{"name":"ADC Therapeutics S.A.","slug":"adc-therapeutics-sa","ticker":"","exchange":"","domain":"adcsa.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2022-01-01","label":"Zynlonta first approved","drug":"Zynlonta","drugSlug":"loncastuximab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ADCT-901","genericName":"ADCT-901","slug":"adct-901","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Zynlonta","genericName":"LONCASTUXIMAB","slug":"loncastuximab","indication":"relapsed or refractory large B-cell lymphoma","status":"marketed"}]}],"pipeline":[{"name":"ADCT-901","genericName":"ADCT-901","slug":"adct-901","phase":"phase_1","mechanism":"ADCT-901 is an antibody-drug conjugate that delivers a cytotoxic payload to cancer cells via targeted antibody binding.","indications":[],"catalyst":""},{"name":"Zynlonta","genericName":"LONCASTUXIMAB","slug":"loncastuximab","phase":"marketed","mechanism":"Zynlonta works by binding to a specific target on cancer cells, marking them for destruction.","indications":["relapsed or refractory large B-cell lymphoma","diffuse large B-cell lymphoma (DLBCL) not otherwise specified","DLBCL arising from low-grade lymphoma","high-grade B-cell lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"marketed":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}